A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

NCT02512172 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Oral CC-486
DRUG: Romidepsin
DRUG: MK-3475

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]